BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35293206)

  • 1. Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry.
    Ferhati X; Jiménez-Moreno E; Hoyt EA; Salluce G; Cabeza-Cabrerizo M; Navo CD; Compañón I; Akkapeddi P; Matos MJ; Salaverri N; Garrido P; Martínez A; Laserna V; Murray TV; Jiménez-Osés G; Ravn P; Bernardes GJL; Corzana F
    J Am Chem Soc; 2022 Mar; 144(12):5284-5294. PubMed ID: 35293206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Ring-Opening Reaction of Succinimide Linkers in ADCs.
    Zheng K; Chen Y; Wang J; Zheng L; Hutchinson M; Persson J; Ji J
    J Pharm Sci; 2019 Jan; 108(1):133-141. PubMed ID: 30458165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of cysteine-linked antibody drug conjugates with N-aryl maleimides.
    Christie RJ; Fleming R; Bezabeh B; Woods R; Mao S; Harper J; Joseph A; Wang Q; Xu ZQ; Wu H; Gao C; Dimasi N
    J Control Release; 2015 Dec; 220(Pt B):660-70. PubMed ID: 26387744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Throughput Cysteine Scanning To Identify Stable Antibody Conjugation Sites for Maleimide- and Disulfide-Based Linkers.
    Ohri R; Bhakta S; Fourie-O'Donohue A; Dela Cruz-Chuh J; Tsai SP; Cook R; Wei B; Ng C; Wong AW; Bos AB; Farahi F; Bhakta J; Pillow TH; Raab H; Vandlen R; Polakis P; Liu Y; Erickson H; Junutula JR; Kozak KR
    Bioconjug Chem; 2018 Feb; 29(2):473-485. PubMed ID: 29425028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of applicable thiol-linked antibody-drug conjugates with improved stability and therapeutic index.
    Wang Y; Xie F; Liu L; Xu X; Fan S; Zhong W; Zhou X
    Drug Deliv; 2022 Dec; 29(1):754-766. PubMed ID: 35244495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.
    Shen BQ; Xu K; Liu L; Raab H; Bhakta S; Kenrick M; Parsons-Reponte KL; Tien J; Yu SF; Mai E; Li D; Tibbitts J; Baudys J; Saad OM; Scales SJ; McDonald PJ; Hass PE; Eigenbrot C; Nguyen T; Solis WA; Fuji RN; Flagella KM; Patel D; Spencer SD; Khawli LA; Ebens A; Wong WL; Vandlen R; Kaur S; Sliwkowski MX; Scheller RH; Polakis P; Junutula JR
    Nat Biotechnol; 2012 Jan; 30(2):184-9. PubMed ID: 22267010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
    Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attachment Site Cysteine Thiol pK
    Vollmar BS; Wei B; Ohri R; Zhou J; He J; Yu SF; Leipold D; Cosino E; Yee S; Fourie-O'Donohue A; Li G; Phillips GL; Kozak KR; Kamath A; Xu K; Lee G; Lazar GA; Erickson HK
    Bioconjug Chem; 2017 Oct; 28(10):2538-2548. PubMed ID: 28885827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term stabilization of maleimide-thiol conjugates.
    Fontaine SD; Reid R; Robinson L; Ashley GW; Santi DV
    Bioconjug Chem; 2015 Jan; 26(1):145-52. PubMed ID: 25494821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the use of DNA as a linker in antibody-drug conjugates: synthesis, stability and in vitro potency.
    Dovgan I; Ehkirch A; Lehot V; Kuhn I; Koniev O; Kolodych S; Hentz A; Ripoll M; Ursuegui S; Nothisen M; Cianférani S; Wagner A
    Sci Rep; 2020 May; 10(1):7691. PubMed ID: 32376903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid.
    Zhang L; Wang Z; Wang Z; Luo F; Guan M; Xu M; Li Y; Zhang Y; Wang Z; Wang W
    Bioconjug Chem; 2021 Jun; 32(6):1094-1104. PubMed ID: 34013721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the Stability of Maleimide-Thiol Conjugation for Drug Targeting.
    Lahnsteiner M; Kastner A; Mayr J; Roller A; Keppler BK; Kowol CR
    Chemistry; 2020 Dec; 26(68):15867-15870. PubMed ID: 32871016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
    Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward a Ferrous Iron-Cleavable Linker for Antibody-Drug Conjugates.
    Spangler B; Kline T; Hanson J; Li X; Zhou S; Wells JA; Sato AK; Renslo AR
    Mol Pharm; 2018 May; 15(5):2054-2059. PubMed ID: 29569925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with
    Muns JA; Montserrat V; Houthoff HJ; Codée-van der Schilden K; Zwaagstra O; Sijbrandi NJ; Merkul E; van Dongen GAMS
    J Nucl Med; 2018 Jul; 59(7):1146-1151. PubMed ID: 29496986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates.
    Lyon RP; Setter JR; Bovee TD; Doronina SO; Hunter JH; Anderson ME; Balasubramanian CL; Duniho SM; Leiske CI; Li F; Senter PD
    Nat Biotechnol; 2014 Oct; 32(10):1059-62. PubMed ID: 25194818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody-drug conjugates.
    Dennler P; Chiotellis A; Fischer E; Brégeon D; Belmant C; Gauthier L; Lhospice F; Romagne F; Schibli R
    Bioconjug Chem; 2014 Mar; 25(3):569-78. PubMed ID: 24483299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.